Stock comparison
Amneal Pharmaceuticals
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AMRX
Amneal Pharmaceuticals
Market cap
$3.96B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AMRX | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 77B | LMAT |
| Benjamin Graham | 57D | 89A | LMAT |
| Philip Fisher | 63C | 81C | LMAT |
| Peter Lynch | 54C | 67B | LMAT |
| Joel Greenblatt | 31F | 56D | LMAT |
| Charlie Munger | 53D | 68D | LMAT |
| Terry Smith | 42D | 69D | LMAT |
Side-by-side metrics
| Metric | AMRX | LMAT |
|---|---|---|
| Market cap | $3.96B | $2.23B |
| P/E (TTM) | 32.1x | 37.1x |
| EV/EBIT | 14.9x | 36.6x |
| ROIC (TTM) | 12.64% | 9.43% |
| Gross margin | 38.66% | 72.39% |
| Net margin | 4.02% | 24.35% |
| Revenue CAGR 5y | 9.58% | 12.75% |
| EPS CAGR 5y | 34.63% | 19.04% |
| Debt / Equity | - | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AMRX leads on
- Debt / Equity-vs 0.5x+101%
- EV/EBIT14.9xvs 36.6x+59%
- EPS CAGR 5y34.63%vs 19.04%+45%
- Market cap$3.96Bvs $2.23B+44%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 4.02%+84%
- Gross margin72.39%vs 38.66%+47%
- Revenue CAGR 5y12.75%vs 9.58%+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.